TY - JOUR AU - Langhorne P. AU - Bernhardt J. AU - Lindley R. AU - Thrift A. AU - Churilov L. AU - Collier J. AU - Donnan G. AU - Dewey H. AU - Hameed S. AU - Lennon S. AU - Raffelt A. AU - Speare S. AU - Ancliffe J. AU - Katijjahbe M. AU - McRae A. AU - Tan D. AU - Quiney J. AU - Williamson H. AB -

OBJECTIVE: The purpose of this paper is to examine potential threats to generalisability of the results of a multicentre randomised controlled trial using data from A Very Early Rehabilitation Trial (AVERT). DESIGN: AVERT is a prospective, parallel group, assessor-blinded randomised clinical trial. This paper presents data assessing the generalisability of AVERT. SETTING: Acute stroke units at 44 hospitals in 8 countries. PARTICIPANTS: The first 20,000 patients screened for AVERT, of whom 1158 were recruited and randomised. MODEL: We use the Proximal Similarity Model, which considers the person, place, and setting and practice, as a framework for considering generalisability. As well as comparing the recruited patients with the target population, we also performed an exploratory analysis of the demographic, clinical, site and process factors associated with recruitment. RESULTS: The demographics and stroke characteristics of the included patients in the trial were broadly similar to population-based norms, with the exception that AVERT had a greater proportion of men. The most common reason for non-recruitment was late arrival to hospital (ie, >24 h). Overall, being older and female reduced the odds of recruitment to the trial. More women than men were excluded for most of the reasons, including refusal. The odds of exclusion due to early deterioration were particularly high for those with severe stroke (OR=10.4, p<0.001, 95% CI 9.27 to 11.65). CONCLUSIONS: A model which explores person, place, and setting and practice factors can provide important information about the external validity of a trial, and could be applied to other clinical trials. TRIAL REGISTRATION NUMBER: Australian New Zealand Clinical Trials Registry (ACTRN12606000185561) and Clinicaltrials.gov (NCT01846247).

AD - Florey Institute of Neuroscience and Mental Health, Heidelberg, Victoria, Australia.
Westmead Clinical School and The George Institute for Global Health, Westmead Hospital C24, Sydney, New South Wales, Australia.
Royal Perth Hospital, Perth, Western Australia, Australia.
Physiotherapy Unit, Medical Rehabilitation Services Department, UKM Medical Centre, Kuala Lumpur, Malaysia.
Singapore General Hospital, Singapore, Singapore.
School of Health Sciences, Flinders University, Repatriation General Hospital, Daw Park, South Australia, Australia.
Community and Long Term Conditions Directorate, Auckland District Health Board, Auckland City Hospital, Auckland, New Zealand.
Department of Physiotherapy, Singapore General Hospital, Singapore, Singapore.
Royal Melbourne Hospital, Parkville, Victoria, Australia.
Department of Physiotherapy, Austin Health, Austin Hospital, Heidelberg, Victoria, Australia.
Florey Institute of Neuroscience and Mental Health, and Faculty of Medicine, Nursing and Health Sciences, Monash University, Box Hill Hospital, Box Hill, Victoria, Australia.
Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia. AN - 26283667 BT - BMJ Open C2 - PMC4550737 DP - NLM ET - 2015/08/19 LA - eng LB - AUS
FY16
PDO M1 - 8 N1 - Bernhardt, Julie
Raffelt, Audrey
Churilov, Leonid
Lindley, Richard I
Speare, Sally
Ancliffe, Jacqueline
Katijjahbe, Md Ali
Hameed, Shahul
Lennon, Sheila
McRae, Anna
Tan, Dawn
Quiney, Jan
Williamson, Hannah C
Collier, Janice
Dewey, Helen M
Donnan, Geoffrey A
Langhorne, Peter
Thrift, Amanda G
AVERT Trialists' Collaboration
Research Support, Non-U.S. Gov't
England
BMJ Open. 2015 Aug 17;5(8):e008378. doi: 10.1136/bmjopen-2015-008378. N2 -

OBJECTIVE: The purpose of this paper is to examine potential threats to generalisability of the results of a multicentre randomised controlled trial using data from A Very Early Rehabilitation Trial (AVERT). DESIGN: AVERT is a prospective, parallel group, assessor-blinded randomised clinical trial. This paper presents data assessing the generalisability of AVERT. SETTING: Acute stroke units at 44 hospitals in 8 countries. PARTICIPANTS: The first 20,000 patients screened for AVERT, of whom 1158 were recruited and randomised. MODEL: We use the Proximal Similarity Model, which considers the person, place, and setting and practice, as a framework for considering generalisability. As well as comparing the recruited patients with the target population, we also performed an exploratory analysis of the demographic, clinical, site and process factors associated with recruitment. RESULTS: The demographics and stroke characteristics of the included patients in the trial were broadly similar to population-based norms, with the exception that AVERT had a greater proportion of men. The most common reason for non-recruitment was late arrival to hospital (ie, >24 h). Overall, being older and female reduced the odds of recruitment to the trial. More women than men were excluded for most of the reasons, including refusal. The odds of exclusion due to early deterioration were particularly high for those with severe stroke (OR=10.4, p<0.001, 95% CI 9.27 to 11.65). CONCLUSIONS: A model which explores person, place, and setting and practice factors can provide important information about the external validity of a trial, and could be applied to other clinical trials. TRIAL REGISTRATION NUMBER: Australian New Zealand Clinical Trials Registry (ACTRN12606000185561) and Clinicaltrials.gov (NCT01846247).

PY - 2015 SN - 2044-6055 (Electronic) EP - e008378 T2 - BMJ Open TI - Exploring threats to generalisability in a large international rehabilitation trial (AVERT) VL - 5 Y2 - FY16 ER -